Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase IIa, Randomized, Double-blind, Placebo Controlled, Parallel Group Study to Assess the Safety and Efficacy of Subcutaneously Administered BI 655066/ABBV-066 (Risankizumab) as add-on Therapy Over 24 Weeks in Patients With Severe Persistent Asthma.

NCT02443298 is registered in ClinicalTrials.gov with AbbVie as lead sponsor.

NCT NCT02443298
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02443298 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase IIa, Randomized, Double-blind, Placebo Controlled, Parallel Group Study to Assess the Safety and Efficacy of Subcutaneously Administered BI 655066/ABBV-066 (Risankizumab) as add-on Therapy Over 24 Weeks in Patients With Severe Persistent Asthma.
Lead sponsor
AbbVie
Phase
Phase 2
Overall status
Completed
Start date
June 23, 2015
Completion date
February 2, 2018
Enrollment
214 (actual)
Sites
65

Conditions

As the registry lists them; a condition with its own page is linked.

asthma